IRCT20120901010703N4招募中2 期
Comparative evaluation of the effects of CPP-ACPF paste and propolis tooth paste on treatment of dentinal hypersensitivity.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients referred to the general and specialized periodontics department of Isfahan Dental School have at least 2 teeth with complaints of cervical dentin sensitivity and sensitivity to cold stimuli that are not adjacent to each other
- •Patients should be available for three months during the study period and sign the informed consent form
- •Teeth do not need restorative treatment
- •People over 18 years old
排除标准
- •Erosion, abrasion, attrition, crack and pulpitis, chronic disease and periodontal disease
- •Existence of active caries, restored teeth, coronary fractures
- •Candidate teeth receiving veneers, teeth with ortho braces
- •People who have received antihistamines, antidepressants, and sedatives in the month before or during the study.
- •Pregnant and lactating people
- •Patients who have used anti-sensitive toothpaste for the past 6 weeks.
- •Milk protein sensitivity
- •Sensitivity to benzoate
- •Improper diet (use of sour and acidic foods)
研究者
相似试验
已完成
不适用
Comparing the effect of two different pastes on dental plaque pH changes and caries prevention after sugar consumption.Dental careis.Dental cariesIRCT2012113010086N2Chancellor of research center of islamic azad dental university,Tehran40
尚未招募
4 期
A clinical trial to compare the effectiveness of two methods of remineralisation using CPP-ACP varnish on white spots on teethCTRI/2020/01/022962King Georges Medical University
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-BEAcerta Pharma, BV60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-GBAcerta Pharma B.V.60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-ESAcerta Pharma, BV80